Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Redhill Biopharma Ltd and IntelGenx provide an update on FDA's ongoing review of NDA for RHB-103 Oral Migraine Film


Thursday, 24 Apr 2014 08:00am EDT 

Redhill Biopharma Ltd and IntelGenx Corp:Canadian drug delivery company focusing on oral drug delivery, reported that US FDA acknowledged receipt of their response to complete Response Letter for RHB-103.RHB-103 New Drug Application NDA and has requested further clarifications.RHB-103 is proprietary oral thin film formulation of rizatriptan for treatment of acute migraines. 

Company Quote

337.5
-8.0 -2.31%
30 Oct 2014